Photo from Nitin Jain/X
Feb 26, 2024, 19:14
Nitin Jain: Our trial of ponatinib VEN + mini-CVD for R/R T-ALL is now open
Nitin Jain, the Director of the Leukemia CAR-T Program at the MD Anderson Cancer Center, shared on X/Twitter:
“Excited to share that our trial of ponatinib (as LCK inhibitor) + VEN + mini-CVD for R/R T-ALL is now open. Joint collaboration with MDACC and St Jude Hospital.
Jun Yang and Jiyang Yu showed 40% T-ALL overexpress LCK and sensitive to ponatinib/dasatinib (Notably, none had ABL fusion).
This trial is supported by The Leukemia and Lymphoma Society LLS TRP grant. A truly unmet medical need. Please DM or email me for any potential patients.”
Source: Nitin Jain/X
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
Nov 14, 2024, 00:19
Nov 14, 2024, 00:02
Nov 13, 2024, 23:57
Nov 13, 2024, 23:54
Nov 13, 2024, 23:48
Nov 13, 2024, 23:46